Monthly Communication Report

Corporation:	AstraZeneca Canada Inc.
Associated registration:	957438-15042-64
Communication date:	2026-02-23
Posted date:	2026-03-16

Designated Public Office Holders who participated in the communication:	Loris Mirella, Director, Intellectual Property, Trade Policy Global Affairs Canada (GAC) Dominic LeBlanc, President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs Global Affairs Canada (GAC) Sandenga Yeba, Director of Policy & Deputy Chief of Staff Office of the Minister of Health, Health Canada (HC) Shalene Curtis Micallef, Deputy Minister Health Canada (HC) Karim Bardeesy, Member of Parliament House of Commons Ritu Banerjee, Assistant Deputy Minister Office of Life Sciences and Manufacturing Readiness, Innovation, Science and Economic Development Canada (ISED) Martin Moen, Associate Assistant Deputy Minister Global Affairs Canada (GAC) Manuela Tomic, Senior Policy Advisor Minister of Industry and Minister Responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED) Daniel MacDonald, Director General Drugs for Rare Disease, Health Canada (HC) Nasser Haidar, Senior Policy Advisor Office of the Min. responsible for Canada-U.S. Trade, Intergovernmental Affairs and One Canadian Economy, Intergovernmental Affairs Secretariat (IGA) Footnote1 Marjorie Michel, Minister of Health Ministry of Health, Health Canada (HC) Justine Frame, Special Assistant, Policy Minister's Office, Health Canada (HC) Janice Charette, Chief Trade Negotiator to the US Global Affairs Canada (GAC)
List of Details Subject matter Detail Economic Development, Health, International Trade, Research and Development, Taxation and Finance Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry Economic Development, Federal-Provincial Relations, Health, Industry, Intellectual Property, Research and Development Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Budget, Economic Development, Federal-Provincial Relations, Foreign Affairs, Government Procurement, Health, Industry, International Trade, Research and Development Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Responsible Officer who filed this communication report:	Gaby Bourbara
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.
Footnote1  Indicates new information that was added through a monthly communications return.